文献速递外周动脉疾病

慢性肢体威胁性缺血成本-效用分析的系统评价

A Systematic Review of Cost-Utility Analyses in Chronic Limb-Threatening Ischemia.
PubMed 文献 · Ann Vasc Surg · 2022-05-11

该系统评价检索了截至2021年8月的六个文献数据库和在线注册库,纳入3项试验基于研究和5项模型基于研究,评估血运重建、大截肢或保守治疗在成人慢性肢体威胁性缺血中的成本-效用。血运重建在腹股沟下病变中可能优于大截肢或保守治疗,但数据不足以推荐特定治疗。

要点

  • 共纳入8项成本-效用分析研究(3项试验基于,5项模型基于),多数评估腹股沟下病变并从医疗服务提供者视角分析。
  • 开放手术血运重建的增量成本效果比为3,678、58,828和72,937美元,可能比保守治疗更具成本效果。
  • 血管内血运重建的增量成本效果比为52,036、125,329和149,123美元,混合开放或血管内血运重建为8,094美元。

核心结论

  • 慢性肢体威胁性缺血中成本-效用分析的应用尚处于起步阶段。
  • 腹股沟下病变的血运重建可能优于大截肢或保守治疗。
  • 数据不足以支持推荐特定治疗。

研究设计与样本

  • 系统评价,检索六个文献数据库和在线注册库中截至2021年8月的英文文献,注册号CRD42021273602。
  • 纳入评估血运重建(开放手术或血管内)、大截肢或保守治疗的成人慢性肢体威胁性缺血成本-效用分析研究。
  • 共纳入3项试验基于研究和5项模型基于研究,结局指标为质量调整生命年,采用增量成本效果比比较并转换为2021年美元。
  • 使用2022年CHEERS声明评估研究报告质量。

主要发现

  • 研究满足CHEERS声明28项标准中的14至20项,仅1项研究按标准化报告指南撰写。
  • 多数研究评估腹股沟下病变并采用医疗服务提供者视角。
  • 各研究呈现的增量成本效果比差异很大。
  • 开放手术血运重建的增量成本效果比为3,678、58,828和72,937美元,可能比保守治疗更具成本效果。
  • 血管内血运重建的增量成本效果比为52,036、125,329和149,123美元,混合开放或血管内血运重建为8,094美元,可能比保守治疗更具成本效果。

关键数值与推荐

  • 开放手术血运重建的增量成本效果比:3,678、58,828和72,937美元(2021年美元)。
  • 血管内血运重建的增量成本效果比:52,036、125,329和149,123美元(2021年美元)。
  • 混合开放或血管内血运重建的增量成本效果比:8,094美元(2021年美元)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 成本-效用分析在慢性肢体威胁性缺血中的应用尚处于起步阶段。
  • 数据不足以支持推荐特定治疗。
  • 各研究增量成本效果比差异很大。
  • 仅1项研究按标准化报告指南撰写。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To review and describe the available literature on cost-utility analysis of revascularization and non-revascularization treatment approaches in chronic limb-threatening ischemia. METHODS: A systematic review was performed on cost-utility analysis studies evaluating revascularization (open surgery or endovascular), major lower extremity amputation, or conservative management in adult chronic limb-threatening ischemia patients. Six bibliographic databases and online registries were searched for English language articles up to August 2021. The outcome for cost-utility analysis was quality-adjusted in life years. Procedures were compared using incremental cost-effectiveness ratios which were converted to 2021 United States dollars. Study reporting quality was assessed using the 2022 Consolidated Health Economic Evaluation Reporting Standards statement. The study was registered in International Prospective Register of Systematic Reviews (CRD42021273602). RESULTS: Three trial-based and five model-based studies were included for review. Studies met between 14/28 and 20/28 criteria of the Consolidated Health Economic Evaluation Reporting Standards CHEERS statement. Only one study was written according to standardized reporting guidelines. Most studies evaluated infrainguinal disease, and adopted a health care provider perspective. There was a large variation in the incremental cost-effectiveness ratios presented across studies. Open surgical revascularization (incremental cost-effectiveness ratios: $3,678, $58,828, and $72,937), endovascular revascularization (incremental cost-effectiveness ratios: $52,036, $125,329, and $149,123), and mixed open or endovascular revascularization (incremental cost-effectiveness ratio: $8,094) maybe more cost-effective than conservative management. CONCLUSIONS: The application of cost-utility analyses in chronic limb-threatening ischemia is in its infancy. Revascularization in infrainguinal disease may be favored over major lower extremity amputation or conservative management. However, data is inadequate to support recommendations for a specific treatment. This review identifies short and long-term considerations to address the current state of evidence. Cost-utility analysis is an important tool in healthcare policy and should be encouraged amongst the vascular surgical community.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shan LL, Wang J, Westcott MJ, et al. A Systematic Review of Cost-Utility Analyses in Chronic Limb-Threatening Ischemia. Ann Vasc Surg. 2022. PMID: 35561892. doi:10.1016/j.avsg.2022.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。